KLK3 and posterior cortical atrophy: Notably, A-485 treatment could inhibit DHT-stimulated PSA expression more potently than the AR antagonist enzalutamide via reducing the deposition of H3K27ac at the PSA promoter and inhibited the proliferation of PCa cells (144).